RANBAXY

Sun Pharmaceuticals Industries Limited has informed the Exchange that the Company has fixed Record Date as April 7, 2015 to determine the names of the shareholders of erstwhile Ranbaxy who would be entitled to receive 8 ( eight) equity shares of Re.1 each of the Company for every 10 (ten) equity shares of Rs.5 each of erstwhile Ranbaxy held and to determine the names of the NCD holders who would be entitled to 1 (One) NCD of Rs.1 lac each of the Company for every 1 (One) NCD of Rs.1 lac each held in erstwhile Ranbaxy pursuant to amalgamation of erstwhile Ranbaxy into the Company.

Ranbaxy Laboratories Limited has informed the Exchange that the Allotment Committee of Directors at its meeting held on November 25, 2014, allotted 450,000 Equity Shares of Rs.5 each for cash at par to Ranbaxy ESOP Trust (Trust), set up to administer Ranbaxy Employee Stock Option Plan-2011. The Trust would allocate the shares to the employees of the Company and its subsidiaries on exercise of stock options from time to time under Ranbaxy Employee Stock Option Plan 2011. The paid-up Equity Share Capital of the Company post allotment is 425,022,900 Equity Shares of Rs.5 each aggregating Rs.2,125

Ranbaxy Laboratories Limited has informed the Exchange that the Company has fixed Book Closure from July 19, 2014 to July 28, 2014 for the purpose of Annual general Meeting of the Company to be held on July 28, 2014.

Ranbaxy Laboratories Limited has informed the Exchange that the ESOPs Allotment Committee of Directors vide Resolution by Circulation passed on January 10, 2014, allotted 37,281 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 423,779,063 Equity Shares of Rs.5 each aggregating Rs, 2,118,895,315/-.

Ranbaxy Laboratories Limited has informed the Exchange that the Allotment Committee of Directors through Resolution by Circulation passed on December 11. 2013, allotted 600,000 Equity Shares of Rs. 5 each for cash at par to Ranbaxy ESOP Trust (Trust), set up to administer Ranbaxy Employee Stock Option Plan-2011. The Trust would allocate the shares to the employees of the Company and of its subsidiaries on exercise of stock options from time to time under Ranbaxy Employee Stock Option Plan - 2011.The paid-up Equity Share Capital of the Company post allotment is 423,741,782 Equity Shares of Rs.

Ranbaxy Laboratories Limited has informed the Exchange that the ESOPs Allotment Committee of Directors vide Resolution by Circulation passed on July 10, 2013, allotted 28,520 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 423,129,509 Equity Shares of Rs. 5 each aggregating Rs. 2,115,647,545/-.

Ranbaxy Laboratories Limited has informed the Exchange that the ESOPs Allotment Committee of Directors vide Resolution by Circulation passed on April 15, 2013, allotted 94,136 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 423,100,989 Equity Shares of Rs. 5 each aggregating Rs. 2,115,504,945/-.

Ranbaxy Laboratories Limited has informed the Exchange that the Board of Directors at its meeting held on February 26, 2013 has decided to convene the Annual General Meeting (AGM) of the Company on May 07, 2013. Share transfer books for the purpose of AGM will remain closed from April 27, 2013 to May 07, 2013 (both days inclusive).

Ranbaxy Laboratories Limited has informed the Exchange that the ESOPs Allotment Committee of Directors vide Resolution by Circulation passed on January 11, 2013, allotted 93,050 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 423,006,853 Equity Shares of Rs. 5 each aggregating Rs. 2,115,034,265/-.

Ranbaxy Laboratories Limited has informed the Exchange that the Allotment Committee of Directors through Resolution by Circulation passed on December 21, 2012, allotted 440,000 Equity Shares of Rs.5 each for cash at par to Ranbaxy ESOP Trust (Trust), set up to administer Ranbaxy Employee Stock Option Plan-2011. The Trust would allocate the shares to the employees of the Company and of its subsidiaries on exercise of stock options from time to time under Ranbaxy Employee Stock Option Plan - 2011. The paid-up Equity Share Capital of the Company post allotment is 422,913,803 Equity Shares of Rs.5

Ranbaxy Laboratories Limited has informed the Exchange that the ESOPs Allotment Committee of Directors vide Resolution by Circulation passed on October 11, 2012, allotted 208,854 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 422,473,803 Equity Shares of Rs. 5 each aggregating Rs. 2,112,369,015/-.

Ranbaxy Laboratories Limited has informed the Exchange that the ESOPs Allotment Committee of Directors vide Resolution by Circulation passed on July 11, 2012, allotted 152,361 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 422,264,949 Equity Shares of Rs. 5 each aggregating Rs. 2,111,324,745/-.

Ranbaxy Laboratories Limited has informed the Exchange that the ESOPs Allotment Committee of Directors vide Resolution by Circulation passed on April 17, 2012, allotted 80,898 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 422,112,588 Equity Shares of Rs. 5 each aggregating Rs. 2,110,562,940/-.

Ranbaxy Laboratories Limited has informed the Exchange that the Board of Directors at its meeting held on February 23, 2012 has decided to (1) convene the Annual General Meeting (AGM) of the Company on Tuesday, May 8, 2012. Share transfer books for the purpose of AGM will remain closed from April 28, 2012 to May 8, 2012 (both days inclusive).

Ranbaxy Laboratories Limited has informed the Exchange that the ESOPs Allotment Committee of Directors vide Resolution by Circulation passed on January 13, 2012, allotted 31,966 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 422,031,690 Equity Shares of Rs. 5 each aggregating Rs. 2,110,158,450/-.

Ranbaxy Laboratories Limited has informed the Exchange that the ESOPs Allotment Committee of Directors vide Resolution by Circulation passed on October 12, 2011, allotted 167,798 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 421,999,724 Equity Shares of Rs. 5 each aggregating Rs. 2,109,998,620/-.

Ranbaxy Laboratories Limited has informed the Exchange that the Allotment Committee of Directors vide Resolution by Circulation passed on October 04, 2011, allotted 325,000 Equity Shares of Rs.5 each for cash at par to Ranbaxy ESOP Trust (Trust), set up to administer Ranbaxy Employee Stock Option Plan-2011. The Trust would allocate the shares to the employees of the Company and of its subsidiaries on exercise of stock options from time to time under Ranbaxy Employee Stock Option Plan-2011. The paid-up Equity Share Capital of the Company post allotment is 421,831,926 Equity Shares of Rs.5 each

Ranbaxy Laboratories Limited has informed the Exchange that the ESOPs Allotment Committee of Directors vide Resolution by Circulation passed on July 12, 2011 allotted 143,696 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 421,506,926 Equity Shares of Rs. 5 each aggregating Rs. 2,107,534,630/-.

Ranbaxy Laboratories Limited has informed the Exchange that at the meeting of Board of Directors held on February 22, 2011: (1) Annual General Meeting (AGM) of the Company has been fixed for May 09, 2011. (2) Share Transfer books for the purpose of dividend will remain closed from April 30, 2011 to May 09, 2011 (both days inclusive).

Ranbaxy Laboratories Limited has informed the Exchange that the ESOPs Allotment Committee of Directors vide Resolution by Circulation passed on January 11, 2011, allotted 211,615 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 421,252,308 Equity Shares of Rs.5 each aggregating Rs.2,106,261,540/-.

Ranbaxy Laboratories Limited has informed the Exchange that the ESOPs Allotment Committee of Directors vide Resolution by Circulation passed on October 08,2010 allotted 286,536 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 421,040,693 Equity Shares of Rs. 5 each aggregating Rs. 2,105,203,465/-.

Ranbaxy Laboratories Limited has informed the Exchange that the ESOPs Allotment Committee of Directors vide Resolution by Circulation passed on July 12, 2010, allotted 85,955 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 420,754,157 Equity Shares of Rs. 5 each aggregating Rs. 2,103,770,785/-.

Ranbaxy Laboratories Ltd has informed the Exchange that the Annual General Meeting of the Company has been fixed for May 10, 2010 and share transfer books for this purpose will remain closed from May 03, 2010 to May 10, 2010 (both days inclusive).

Ranbaxy Laboratories Ltd has informed the Exchange that the Board at its meeting held on March 27, 2009 has approved the following: (1) Annual General Meeting (AGM) has been fixed for May 29, 2009. (2) Share transfer books for the purpose of AGM will remain closed from May 22, 2009 to May 29, 2009 (both days inclusive).

ICICI Securities Limited has informed the Exchange that pursuant to the SEBI (Substantial Acquisition of shares and takeovers) Regulations, 1997 and subsequent amendments thereto, Daiichi Sankyo Company Limited (referred to as the "Acquirer") is making an offer to the public shareholders of Ranbaxy Laboratories Limited ("RLL"), to acquire up to 92,519,126 fully paid-up equity shares of RLL, representing 20% of the emerging voting capital of RLL at a price of Rs. 737 per equity share, payable in cash (referred to as the "Offer"). ICICI securities Limited is acting as the Manager to the offer.

ICICI Securities Limited has informed the Exchange regarding the Public Announcement published on June 16, 2008 ('PA') published in the newspaper. As per the PA, pursuant to the SEBI (Substantial Acquisition of Shares and Takeovers), Regulations, 1997, as amended ('the Regulations'), Daiichi Sankyo Company Limited ('Acquirer') had announced making an offer to the public shareholders of Ranbaxy Laboratories Limited ('RLL'), to acquire up to 92,519,126 fully paid-up equity shares of RLL, representing 20% of the emerging voting capital of RLL at a price of Rs. 737 per equity share of face value o

ICICI Securities Limited has informed the Exchange regarding a public announcement ("PA") being issued by them (the 'Manager to the Offer') for and on behalf of Daiichi Sankyo Company, Limited ('Daiichi Sankyo' or the 'Acquirer') pursuant to Regulation 10 and 12 of and as required under the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 1997 as amended (the 'Regulations'). The Offer: This offer (the 'Offer') is being made by the Acquirer to the equity shareholders of Ranbaxy Laboratories Limited (hereinafter referred to as 'RLL' or the 'Ta

Ranbaxy Laboratories Ltd has informed the Exchange that: 1) Share transfer books for the purpose of determination of entitlement of final dividend will remain closed from May 23, 2008 to May 30, 2008 (both days inclusive). 2) Annual General Meeting has been fixed May 30, 2008. Further the Company has submitted a copy of Audited Accounts for the year ended December 31, 2007. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_upd

Ranbaxy Laboratories Ltd has informed the Exchange that the Share Transfer Books of the Company for the purpose of Annual General Meeting will remain closed from May 25, 2007 to May 31, 2007 (both days inclusive). Annual General Meeting has been fixed for May 31, 2007.

Ranbaxy Laboratories Ltd has informed the Exchange that April 05, 2007 has been fixed as the Record Date for determination of entitlement of 2nd Interim Dividend for the year ended December 31, 2006.

Ranbaxy Laboratories Ltd has informed the Exchange that the Record Date for determination of entitlement of the interim dividend has been fixed as November 03, 2006. Interim Dividend will be paid to the eligible shareholders on or before November 14, 2006.

Ranbaxy Laboratories Ltd has informed the Exchange that Share transfer books for the purpose of determination of entitlement of final dividend will remain closed from June 17, 2006 to June 28, 2006 (both days inclusive). Further, Annual General Meeting has been fixed for June 28, 2006.

Ranbaxy Laboratories Ltd has informed the Exchange as follows: 1) The Shareholders of the Company at the AGM held on June 30, 2005 inter-alia have approved sub-division of equity shares of the company from face value of Rs.10 per share to Rs.5 per share; 2) The company has fixed August 01, 2005 as the Record Date for sub-division of the equity shares of the company from face value of Rs.10 per share to Rs.5 per share.

Ranbaxy Laboratories Ltd has informed the Exchange that The Calcutta Stock Exchange Association Limited vide their letter dated October 25, 2004 has informed the Company that their request for voluntary delisting of the securities of the Company has been approved by the Exchange on September 30, 2004 and that Notice for delisting is being issued by the Exchange. However, the securities of the Company will be traded under the 'Permitted Category' on the Exchange.